See more : Swancor Advanced Materials Co., Ltd. (688585.SS) Income Statement Analysis – Financial Results
Complete financial analysis of MiNK Therapeutics, Inc. (INKT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MiNK Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shanghai International Airport Co., Ltd. (600009.SS) Income Statement Analysis – Financial Results
- Covestro AG (1COV.F) Income Statement Analysis – Financial Results
- Capital Bancorp, Inc. (CBNK) Income Statement Analysis – Financial Results
- Sprague Resources LP (SRLP) Income Statement Analysis – Financial Results
- Modiv Inc. (MDV) Income Statement Analysis – Financial Results
MiNK Therapeutics, Inc. (INKT)
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 2.70B | 0.00 | 0.00 | 689.63K |
| Cost of Revenue | 204.62K | 30.95B | 28.36B | 55.06K | 0.00 |
| Gross Profit | -204.62K | -28.24B | -28.36B | -55.06K | 689.63K |
| Gross Profit Ratio | 0.00% | -1,044.26% | 0.00% | 0.00% | 100.00% |
| Research & Development | 15.49M | 23.12M | 13.97M | 9.51M | 19.65M |
| General & Administrative | 7.43M | 7.83M | 4.64M | 1.29M | 3.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.43M | 7.83M | 4.64M | 1.29M | 3.83M |
| Other Expenses | 0.00 | 2.70M | -9.53M | -3.00M | 551.24K |
| Operating Expenses | 22.92M | 30.95M | 18.61M | 10.80M | 23.48M |
| Cost & Expenses | 22.92M | 30.95M | 18.61M | 10.80M | 23.48M |
| Interest Income | 463.26K | 253.32K | 2.43K | 2.44K | 1.56K |
| Interest Expense | 0.00 | 253.32K | 2.43M | 2.44M | 1.56M |
| Depreciation & Amortization | 204.62K | 121.75K | 77.96K | 55.06K | 36.82K |
| EBITDA | -22.25M | -30.83M | -27.70M | -13.74M | -22.20M |
| EBITDA Ratio | 0.00% | -1.14% | 0.00% | 0.00% | -3,219.79% |
| Operating Income | -22.92M | -30.95M | -28.36M | -14.64M | -22.28M |
| Operating Income Ratio | 0.00% | -1.14% | 0.00% | 0.00% | -3,231.39% |
| Total Other Income/Expenses | 463.25K | 2.96M | -1.85M | -1.60M | -1.52M |
| Income Before Tax | -22.46M | -27.99M | -30.21M | -16.24M | -23.80M |
| Income Before Tax Ratio | 0.00% | -1.03% | 0.00% | 0.00% | -3,451.46% |
| Income Tax Expense | 0.00 | -3.21M | -7.10M | -560.38K | 2.11M |
| Net Income | -22.46M | -24.78M | -23.11M | -15.68M | -25.91M |
| Net Income Ratio | 0.00% | -0.92% | 0.00% | 0.00% | -3,757.73% |
| EPS | -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| EPS Diluted | -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| Weighted Avg Shares Out | 34.36M | 33.67M | 33.48M | 33.09M | 33.09M |
| Weighted Avg Shares Out (Dil) | 34.36M | 33.67M | 33.48M | 33.09M | 33.09M |
MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know
MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for July 11th
SKIL, INKT, MLCO, GTLB, and HRTX have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2024.
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Zack Armen - Head, Investor Relations Jennifer Buell - President and Chief Executive Officer Marc Van Dijk - Chief Scientific Officer Christine...
MiNK Reports First Quarter 2024 Results
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
MiNK Therapeutics, Inc. (INKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Source: https://incomestatements.info
Category: Stock Reports